FDA Rejects Dapagliflozin for Type 1 Diabetes
Aug 31, 2019
Editor: Steve Freed, R.PH., CDE
Author: Kassey James, Pharm.D. Candidate, LECOM School of Pharmacy
The Food and Drug Administration’s recent response letter stated that it would not approve the drug application for dapagliflozin as add on therapy to insulin for type 1 diabetes. Unlike the United States, Europe approved dapagliflozin for use in type 1 diabetes....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.